Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar for Post-transplant FSGS
NCT02399462Phase 4Withdrawn
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of repository corticotropin injection in focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: number of patients with proteinuria at 52 weeks. Planned start Mar 2021; status: withdrawn.
02
Drugs
repository corticotropin injection
03
Conditions
focal segmental glomerulosclerosis (FSGS)membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT02399462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399462.